Nexalin Technology Files S-1/A Amendment

TL;DR

Nexalin Tech filed an S-1/A amendment on Jan 10, 2025. Still working on their public offering.

AI Summary

Nexalin Technology, Inc. filed an S-1/A amendment on January 10, 2025, for its registration statement. The company, incorporated in Delaware with its principal executive offices in Houston, TX, is involved in the electromedical and electrotherapeutic apparatus industry. This filing is an amendment to a previous registration statement, indicating ongoing efforts to comply with SEC regulations for public offerings.

Why It Matters

This S-1/A filing is a procedural step for Nexalin Technology, Inc. as it continues its process towards a potential public offering or other securities-related transactions, impacting its future capital structure and regulatory standing.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant corporate events like IPOs or secondary offerings, which carry inherent market and execution risks.

Key Numbers

• 333-283960 — SEC Registration Number (Identifies the specific registration filing with the SEC.)
• 27-5566468 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Nexalin Technology, Inc. (company) — Registrant
• 333-283960 (dollar_amount) — SEC Registration Number
• January 10, 2025 (date) — Filing Date
• Mark White (person) — Chief Executive Officer
• Martin S. Siegel, Esq. (person) — Agent for Service Counsel

FAQ

Key Financial Figures

• $0.001 — ares”) of common stock, par value $0.001 per share of Nexalin Technology, Inc. (
• $2.97 — q Capital Market on January 9, 2025 was $2.97 per share. We are an “emerging

Filing Documents

• nexalintech_s1a1.htm (S-1/A) — 384KB
• nexalintech_ex5-1.htm (EX-5.1) — 12KB
• nexalintech_ex23-1.htm (EX-23.1) — 3KB
• img_001.jpg (GRAPHIC) — 11KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• 0001829126-25-000158.txt ( ) — 421KB

Use of Proceeds

Use of Proceeds 29 Dividend Policy 30 September 2022 Public Offering 31 Selling Stockholders 32

Description of Securities

Description of Securities 34 Plan of Distribution 38 Legal Matters 40 Experts 40 Where You Can Find Additional Information 40 Incorporation of Certain Information by Reference 41 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time up to an aggregate of 2,798,613 shares of common stock, par value $0.001 per share (“Common Stock”), of Nexalin Technology, Inc. (the “Company”, “we”, “us” or “our”), consisting of (i) up to 347,250 shares of Common Stock issuable upon the exercise of the common stock purchase warrant that was issued to Maxim Partners, LLC (“Maxim Partners”) as compensation for its services in connection with the Company’s 2022 initial public offering; (ii) up to 2,315,000 shares of Common Stock issuable upon the exercise of the common stock purchase warrants issued to purchasers of Units (containing both a share of common stock and a common stock purchase warrant) in connection the Company’s 2022 public offering; and (iii) 136,363 shares of Common Stock issued to Maxim Partners pursuant to a renewal of its engagement agreement with the Company. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the shares of Common Stock offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from

View Full Filing

View this S-1/A filing on SEC EDGAR